The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma

The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma

Abstract Background PARP1 facilitates the recovery of DNA-damaged cells by recruiting DNA damage response molecules such as γH2AX and BRCA1/2, and plays a role in resistance to antitumor therapies. Therefore, PARP inhibition being evaluated as an anti-cancer therapy. However, there are limited studi...

Full description

Bibliographic Details
Main Authors: Hye Jeong Park, Jun Sang Bae, Kyoung Min Kim, Young Jae Moon, See-Hyoung Park, Sang Hoon Ha, Usama Khamis Hussein, Zhongkai Zhang, Ho Sung Park, Byung-Hyun Park, Woo Sung Moon, Jung Ryul Kim, Kyu Yun Jang
Format: Article
Language:English
Published: BMC 2018-05-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Osteosarcoma
PARP1
Olaparib
Doxorubicin
Prognosis
Online Access:http://link.springer.com/article/10.1186/s13046-018-0772-9

Internet

http://link.springer.com/article/10.1186/s13046-018-0772-9

Similar Items